The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

By G. Krueger, J. Koo, M. Lebwohl, A. Menter, R. Stern, T. Rolstad. Archives of Dermatology, 2001

1,049 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. (2004, background): “Select groups of patients commonly report dissatisfaction with available therapy”
Etanercept as monotherapy in patients with psoriasis. (2003, unknown): “Asthenia 5 (3) 7 (4) 6 (4) 3 (2) 5 (3) 2 (1) 9 (6) 12 (7) 5 (3)”
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). (2008, background): “global assessment, a patient’s psoriasis is assessed as cleared (0), minimal ( 1 ), mild (2), moderate (3), marked (4), or severe (5).”
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008, background): “PSYCHIATRIC/PSYCHOLOGIC COMORBIDITIES Depression/suicide Psoriasis is associated with lack of self-esteem and increased prevalence of mood disorders including depression.(29) The prevalence of depression in patients with psoriasis may be as high as 60%.”